Elena Lesma

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi Chromatin Remodeling by Rosuvastatin Normalizes TSC2-/meth Cell Phenotype through the Expression of Tuberin
    Elena Lesma
    Laboratories of Pharmacology, Department of Health Sciences, Universita degli Studi di Milano, Via di Rudinì, 8, 20142 Milano, Italy
    J Pharmacol Exp Ther 345:180-8. 2013
  2. ncbi Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice
    Elena Lesma
    Laboratory of Pharmacology, Department of Health Sciences, University of Milan, Italy
    Am J Pathol 181:947-60. 2012
  3. ncbi Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM
    Elena Lesma
    Laboratory of Pharmacology, Department of Medicine, Surgery and Dentistry Polo H San Paolo, Faculty of Medicine, University of Milan, Milan, Italy
    PLoS ONE 3:e3558. 2008
  4. ncbi The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells
    Elena Lesma
    Laboratory of Pharmacology, Dept of Medicine, Surgery, and Dentistry, Via A Di Rudini 8, 20142 Milano, Italy
    Am J Pathol 174:2150-9. 2009
  5. ncbi Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor
    Elena Lesma
    Laboratory of Pharmacology, Faculty of Medicine, University of Milan, Milan, Italy
    Am J Pathol 167:1093-103. 2005
  6. ncbi Survivin expression in tuberous sclerosis complex cells
    Stephana Carelli
    Laboratory of Pharmacology, Department of Medicine, Surgery and Dentistry, University of Milan, Polo H San Paolo, Milano, Italy
    Mol Med 13:166-77. 2007
  7. ncbi A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia
    Maria Vittoria Arcidiacono
    Pharmacological Laboratories, Department of Medicine, Surgery, and Dentistry, San Paolo Hospital, University of Milan, Milan, Italy
    J Nephrol 20:228-33. 2007
  8. ncbi Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells
    Silvia M Sirchia
    Genetica Medica, Farmacologia, Dipartimento di Medicina, Chirurgia e Odontoiatria, Universita di Milano, Italy
    Cancer Res 65:2139-46. 2005
  9. ncbi Co-administration of IGF-I and glycosaminoglycans greatly delays motor neurone disease and affects IGF-I expression in the wobbler mouse: a long-term study
    Alfredo Gorio
    Department of Medicine, Polo H San Paolo, Faculty of Medicine, Milano, Italy
    J Neurochem 81:194-202. 2002

Collaborators

Detail Information

Publications9

  1. ncbi Chromatin Remodeling by Rosuvastatin Normalizes TSC2-/meth Cell Phenotype through the Expression of Tuberin
    Elena Lesma
    Laboratories of Pharmacology, Department of Health Sciences, Universita degli Studi di Milano, Via di Rudinì, 8, 20142 Milano, Italy
    J Pharmacol Exp Ther 345:180-8. 2013
    ..In particular, rosuvastatin appears useful when the disease is originated by epigenetic defects...
  2. ncbi Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice
    Elena Lesma
    Laboratory of Pharmacology, Department of Health Sciences, University of Milan, Italy
    Am J Pathol 181:947-60. 2012
    ..The development of a model to study metastasis by TSC cells will also help to explain how they invade different tissues and metastasize to the lung...
  3. ncbi Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM
    Elena Lesma
    Laboratory of Pharmacology, Department of Medicine, Surgery and Dentistry Polo H San Paolo, Faculty of Medicine, University of Milan, Milan, Italy
    PLoS ONE 3:e3558. 2008
    ..TSC2(-/-) ASM cell proliferation is EGF-dependent...
  4. ncbi The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells
    Elena Lesma
    Laboratory of Pharmacology, Dept of Medicine, Surgery, and Dentistry, Via A Di Rudini 8, 20142 Milano, Italy
    Am J Pathol 174:2150-9. 2009
    ..Additionally, the effect of chromatin-remodeling agents in these cells suggests a further avenue for the treatment of TSC as well as lymphangioleiomyomatosis...
  5. ncbi Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor
    Elena Lesma
    Laboratory of Pharmacology, Faculty of Medicine, University of Milan, Milan, Italy
    Am J Pathol 167:1093-103. 2005
    ..Signal transduction mediated by EGF and IGF-I receptors is therefore involved in A(+) cell survival. These results may offer a novel therapeutic perspective for the treatment of TSC complications and lymphangioleiomyomatosis...
  6. ncbi Survivin expression in tuberous sclerosis complex cells
    Stephana Carelli
    Laboratory of Pharmacology, Department of Medicine, Surgery and Dentistry, University of Milan, Polo H San Paolo, Milano, Italy
    Mol Med 13:166-77. 2007
    ..Future experimental therapies for TSC and LAM may result from the targeted inhibition of survivin, which may enhance sensitivity to TSC2 therapy...
  7. ncbi A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia
    Maria Vittoria Arcidiacono
    Pharmacological Laboratories, Department of Medicine, Surgery, and Dentistry, San Paolo Hospital, University of Milan, Milan, Italy
    J Nephrol 20:228-33. 2007
    ..These findings suggest that in kidney disease, the increased PT cell growth driven by enhanced EGFR could be further aggravated through elevations in integrin beta1 and FAK expression...
  8. ncbi Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells
    Silvia M Sirchia
    Genetica Medica, Farmacologia, Dipartimento di Medicina, Chirurgia e Odontoiatria, Universita di Milano, Italy
    Cancer Res 65:2139-46. 2005
    ....
  9. ncbi Co-administration of IGF-I and glycosaminoglycans greatly delays motor neurone disease and affects IGF-I expression in the wobbler mouse: a long-term study
    Alfredo Gorio
    Department of Medicine, Polo H San Paolo, Faculty of Medicine, Milano, Italy
    J Neurochem 81:194-202. 2002
    ..Co-treatment also prevented the decrease in IGF-I content observed in vehicle-treated wobbler mice forelimb muscles...